Open AccessRepurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine
Author(s) -
Mariana Babayeva,
Zvi G. Loewy
Publication year - 2020
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s275964
Subject(s) - hydroxychloroquine , medicine , chloroquine , pharmacogenomics , pharmacology , drug , adverse effect , dosing , repurposing , pharmacogenetics , drug repositioning , pandemic , covid-19 , intensive care medicine , malaria , disease , immunology , infectious disease (medical specialty) , ecology , biochemistry , chemistry , gene , genotype , biology
A new coronavirus SARS-CoV-2 has been identified as the etiological agent of the severe acute respiratory syndrome, COVID-19, the source and cause of the 2019-20 coronavirus pandemic. Hydroxychloroquine and chloroquine have gathered extraordinary attention as therapeutic candidates against SARS-CoV-2 infections. While there is growing scientific data on the therapeutic effect, there is also concern for toxicity of the medications. The therapy of COVID-19 by hydroxychloroquine and chloroquine is off-label. Studies to analyze the personalized effect and safety are lacking.